NCT03573947View on ClinicalTrials.gov

Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

March 12, 2023

Study Completion Date

June 15, 2023

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Nivolumab

360 mg intravenously every 3 weeks

DRUG

Ipilimumab

1 mg/kg intravenously over 30 minutes

DRUG

Paclitaxel

80 mg/m2 on days 1 and 8 of every 21-day treatment cycle

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
lead

Jeffrey Clarke

OTHER

NCT03573947 - Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC | Biotech Hunter | Biotech Hunter